Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

Genes associated with bowel metastases in ovarian cancer.

Mariani A, Wang C, Oberg AL, Riska SM, Torres M, Kumka J, Multinu F, Sagar G, Roy D, Jung DB, Zhang Q, Grassi T, Visscher DW, Patel VP, Jin L, Staub JK, Cliby WA, Weroha SJ, Kalli KR, Hartmann LC, Kaufmann SH, Goode EL, Shridhar V.

Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31321-6. doi: 10.1016/j.ygyno.2019.06.010. [Epub ahead of print]

PMID:
31204077
2.

Cellular fibroepithelial lesions of the breast: A long term follow up study.

Yasir S, Nassar A, Jimenez RE, Jenkins SM, Hartmann LC, Degnim AC, Frost M, Visscher DW.

Ann Diagn Pathol. 2018 Aug;35:85-91. doi: 10.1016/j.anndiagpath.2018.01.005. Epub 2018 Jan 10.

PMID:
30029048
3.

Evaluation of 2 breast cancer risk models in a benign breast disease cohort.

Frank RD, Winham SJ, Vierkant RA, Frost MH, Radisky DC, Ghosh K, Brandt KR, Sherman ME, Visscher DW, Hartmann LC, Degnim AC, Vachon CM.

Cancer. 2018 Aug;124(16):3319-3328. doi: 10.1002/cncr.31528. Epub 2018 Jun 22.

PMID:
29932456
4.

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia.

Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, Frost MH, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Carter JM, Denison LA, Broderick B, Hartmann LC, Visscher DW, Radisky DC.

J Clin Oncol. 2018 Jun 20;36(18):1840-1846. doi: 10.1200/JCO.2017.75.9480. Epub 2018 Apr 20.

5.

Association between mammographic breast density and histologic features of benign breast disease.

Ghosh K, Vierkant RA, Frank RD, Winham S, Visscher DW, Pankratz VS, Scott CG, Brandt K, Sherman ME, Radisky DC, Frost MH, Hartmann LC, Degnim AC, Vachon CM.

Breast Cancer Res. 2017 Dec 19;19(1):134. doi: 10.1186/s13058-017-0922-6.

6.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

7.

NanoString-based breast cancer risk prediction for women with sclerosing adenosis.

Winham SJ, Mehner C, Heinzen EP, Broderick BT, Stallings-Mann M, Nassar A, Vierkant RA, Hoskin TL, Frank RD, Wang C, Denison LA, Vachon CM, Frost MH, Hartmann LC, Aubrey Thompson E, Sherman ME, Visscher DW, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(2):641-650. doi: 10.1007/s10549-017-4441-z. Epub 2017 Aug 10.

8.

Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution.

Stallings-Mann ML, Heinzen EP, Vierkant RA, Winham SJ, Hoskin TL, Denison LA, Nassar A, Hartmann LC, Visscher DW, Frost MH, Sherman ME, Degnim AC, Radisky DC.

Breast Cancer Res Treat. 2017 Nov;166(1):133-143. doi: 10.1007/s10549-017-4413-3. Epub 2017 Jul 27.

9.

Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.

Visscher DW, Frank RD, Carter JM, Vierkant RA, Winham SJ, Heinzen EP, Broderick BT, Denison LA, Allers TM, Johnson JL, Frost MH, Hartmann LC, Degnim AC, Radisky DC.

J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx035.

10.

Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Kommoss S, Winterhoff B, Oberg AL, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, Schroeder W, Burges A, Canzler U, Chien J, Embleton AC, Parmar M, Kaplan R, Perren T, Hartmann LC, Goode EL, Dowdy SC, Pfisterer J.

Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3.

11.

Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.

Vierkant RA, Degnim AC, Radisky DC, Visscher DW, Heinzen EP, Frank RD, Winham SJ, Frost MH, Scott CG, Jensen MR, Ghosh K, Manduca A, Brandt KR, Whaley DH, Hartmann LC, Vachon CM.

BMC Cancer. 2017 Jan 31;17(1):84. doi: 10.1186/s12885-017-3082-2.

12.

Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients.

Mullooly M, Yang HP, Falk RT, Nyante SJ, Cora R, Pfeiffer RM, Radisky DC, Visscher DW, Hartmann LC, Carter JM, Degnim AC, Stanczyk FZ, Figueroa JD, Garcia-Closas M, Lissowska J, Troester MA, Hewitt SM, Brinton LA, Sherman ME, Gierach GL.

Breast Cancer Res. 2017 Jan 19;19(1):8. doi: 10.1186/s13058-016-0791-4.

13.

Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study.

Figueroa JD, Pfeiffer RM, Brinton LA, Palakal MM, Degnim AC, Radisky D, Hartmann LC, Frost MH, Stallings Mann ML, Papathomas D, Gierach GL, Hewitt SM, Duggan MA, Visscher D, Sherman ME.

Breast Cancer Res Treat. 2016 Aug;159(1):163-72. doi: 10.1007/s10549-016-3908-7. Epub 2016 Aug 3.

14.

Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.

Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW.

Cancer. 2016 Oct;122(19):2971-8. doi: 10.1002/cncr.30153. Epub 2016 Jun 28.

15.

Breast cancer risk by the extent and type of atypical hyperplasia.

Degnim AC, Visscher DW, Radisky DC, Frost MH, Vierkant RA, Frank RD, Winham SJ, Vachon CM, Dupont WD, Hartmann LC.

Cancer. 2016 Oct;122(19):3087-8. doi: 10.1002/cncr.30151. Epub 2016 Jun 28. No abstract available.

16.

Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

Hartmann LC, Lindor NM.

N Engl J Med. 2016 Jun 16;374(24):2404. doi: 10.1056/NEJMc1602861. No abstract available.

PMID:
27305204
17.

Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer.

Wang C, Winterhoff BJ, Kalli KR, Block MS, Armasu SM, Larson MC, Chen HW, Keeney GL, Hartmann LC, Shridhar V, Konecny GE, Goode EL, Fridley BL.

Br J Cancer. 2016 Jun 14;114(12):1412-20. doi: 10.1038/bjc.2016.124. Epub 2016 Jun 2.

18.

Natural history of age-related lobular involution and impact on breast cancer risk.

Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, Hoskin TL, Nassar A, Vachon CM, Denison LA, Hartmann LC, Frost MH, Degnim AC.

Breast Cancer Res Treat. 2016 Feb;155(3):423-30. doi: 10.1007/s10549-016-3691-5. Epub 2016 Feb 4.

19.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

Hartmann LC, Lindor NM.

N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523. Review. No abstract available.

PMID:
26840135
20.

Mucocele-like lesions of the breast: a clinical outcome and histologic analysis of 102 cases.

Meares AL, Frank RD, Degnim AC, Vierkant RA, Frost MH, Hartmann LC, Winham SJ, Visscher DW.

Hum Pathol. 2016 Mar;49:33-8. doi: 10.1016/j.humpath.2015.10.004. Epub 2015 Oct 31.

21.

PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.

Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JM, Dong H, Hedin KE, Dietz AB, Goode EL, Knutson KL.

Cancer Res. 2016 Jan 15;76(2):239-50. doi: 10.1158/0008-5472.CAN-15-0748. Epub 2015 Nov 13.

22.

Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.

Visscher DW, Frost MH, Hartmann LC, Frank RD, Vierkant RA, McCullough AE, Winham SJ, Vachon CM, Ghosh K, Brandt KR, Farrell AM, Tarabishy Y, Hieken TJ, Haddad TC, Kraft RA, Radisky DC, Degnim AC.

Cancer. 2016 Feb 1;122(3):378-85. doi: 10.1002/cncr.29766. Epub 2015 Oct 29.

23.

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL.

Cancer Immunol Immunother. 2015 Dec;64(12):1495-504. doi: 10.1007/s00262-015-1753-x. Epub 2015 Aug 23.

24.

ERβ expression and breast cancer risk prediction for women with atypias.

Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2015 Nov;8(11):1084-92. doi: 10.1158/1940-6207.CAPR-15-0198. Epub 2015 Aug 14.

25.

Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study.

Nassar A, Visscher DW, Degnim AC, Frank RD, Vierkant RA, Frost M, Radisky DC, Vachon CM, Kraft RA, Hartmann LC, Ghosh K.

Breast Cancer Res Treat. 2015 Sep;153(2):397-405. doi: 10.1007/s10549-015-3535-8. Epub 2015 Aug 12.

26.

Reply to M.H. Gail et al.

Pankratz VS, Degnim AC, Vierkant RA, Frank RD, Hartmann LC.

J Clin Oncol. 2015 Sep 1;33(25):2830-1. doi: 10.1200/JCO.2015.62.5756. Epub 2015 Jul 27. No abstract available.

PMID:
26215951
27.

Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.

Mutter RW, Frost MH, Hoskin TL, Johnson JL, Hartmann LC, Boughey JC.

Breast Cancer Res Treat. 2015 Aug;153(1):183-90. doi: 10.1007/s10549-015-3515-z. Epub 2015 Jul 26.

PMID:
26210521
28.

Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.

Degnim AC, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC.

Breast Cancer Res Treat. 2015 Aug;152(3):687-94. doi: 10.1007/s10549-015-3513-1. Epub 2015 Jul 23.

29.

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.

Chien J, Sicotte H, Fan JB, Humphray S, Cunningham JM, Kalli KR, Oberg AL, Hart SN, Li Y, Davila JI, Baheti S, Wang C, Dietmann S, Atkinson EJ, Asmann YW, Bell DA, Ota T, Tarabishy Y, Kuang R, Bibikova M, Cheetham RK, Grocock RJ, Swisher EM, Peden J, Bentley D, Kocher JP, Kaufmann SH, Hartmann LC, Shridhar V, Goode EL.

Nucleic Acids Res. 2015 Aug 18;43(14):6945-58. doi: 10.1093/nar/gkv111. Epub 2015 Apr 27.

30.

Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.

Nassar A, Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW.

Breast Cancer Res Treat. 2015 May;151(1):89-97. doi: 10.1007/s10549-015-3370-y. Epub 2015 Apr 12.

31.

Atypical hyperplasia of the breast.

Hartmann LC, Degnim AC, Dupont WD.

N Engl J Med. 2015 Mar 26;372(13):1271-2. doi: 10.1056/NEJMc1501046. No abstract available.

PMID:
25806929
32.

Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.

Said SM, Visscher DW, Nassar A, Frank RD, Vierkant RA, Frost MH, Ghosh K, Radisky DC, Hartmann LC, Degnim AC.

Cancer. 2015 May 15;121(10):1548-55. doi: 10.1002/cncr.29243. Epub 2015 Jan 13.

33.

Model for individualized prediction of breast cancer risk after a benign breast biopsy.

Pankratz VS, Degnim AC, Frank RD, Frost MH, Visscher DW, Vierkant RA, Hieken TJ, Ghosh K, Tarabishy Y, Vachon CM, Radisky DC, Hartmann LC.

J Clin Oncol. 2015 Mar 10;33(8):923-9. doi: 10.1200/JCO.2014.55.4865. Epub 2015 Jan 26.

34.

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic.

Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ.

Gynecol Oncol. 2015 Apr;137(1):77-85. doi: 10.1016/j.ygyno.2015.01.539. Epub 2015 Jan 22.

35.

Atypical hyperplasia of the breast--risk assessment and management options.

Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K.

N Engl J Med. 2015 Jan 1;372(1):78-89. doi: 10.1056/NEJMsr1407164. No abstract available.

36.

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC.

Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14.

37.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L.

Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8.

PMID:
25380635
38.

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, Gostout B, Podratz KC, Keeney G, Wang HJ, Hartmann LC, Slamon DJ, Goode EL.

J Natl Cancer Inst. 2014 Sep 30;106(10). pii: dju249. doi: 10.1093/jnci/dju249. Print 2014 Oct.

39.

Impact of reconstruction and reoperation on long-term patient-reported satisfaction after contralateral prophylactic mastectomy.

Boughey JC, Hoskin TL, Hartmann LC, Johnson JL, Jacobson SR, Degnim AC, Frost MH.

Ann Surg Oncol. 2015 Feb;22(2):401-8. doi: 10.1245/s10434-014-4053-3. Epub 2014 Sep 6.

40.

[Assessment of parental stress using the "Eltern-Belastungs-Screening zur Kindeswohlgefährdung" (EBSK) - association with emotional and behavioral problems in children].

Eichler AK, Glaubitz KA, Hartmann LC, Spangler G.

Z Kinder Jugendpsychiatr Psychother. 2014 Jul;42(4):213-22. doi: 10.1024/1422-4917/a000294. German.

PMID:
25005899
41.

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.

Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, Wang C, Tyrer J, Song H, deFazio A, Johnatty SE, Doherty JA, Phelan CM, Sellers TA, Ramirez SM, Vitonis AF, Terry KL, Van Den Berg D, Pike MC, Wu AH, Berchuck A, Gentry-Maharaj A, Ramus SJ, Diergaarde B, Shen H, Jensen A, Menkiszak J, Cybulski C, Lubiłski J, Ziogas A, Rothstein JH, McGuire V, Sieh W, Lester J, Walsh C, Vergote I, Lambrechts S, Despierre E, Garcia-Closas M, Yang H, Brinton LA, Spiewankiewicz B, Rzepecka IK, Dansonka-Mieszkowska A, Seibold P, Rudolph A, Paddock LE, Orlow I, Lundvall L, Olson SH, Hogdall CK, Schwaab I, du Bois A, Harter P, Flanagan JM, Brown R, Paul J, Ekici AB, Beckmann MW, Hein A, Eccles D, Lurie G, Hays LE, Bean YT, Pejovic T, Goodman MT, Campbell I, Fasching PA, Konecny G, Kaye SB, Heitz F, Hogdall E, Bandera EV, Chang-Claude J, Kupryjanczyk J, Wentzensen N, Lambrechts D, Karlan BY, Whittemore AS, Culver HA, Gronwald J, Levine DA, Kjaer SK, Menon U, Schildkraut JM, Pearce CL, Cramer DW, Rossing MA, Chenevix-Trench G; AOCS group; ACS, Pharoah PD, Gayther SA, Ness RB, Odunsi K, Sucheston LE, Knutson KL, Goode EL.

Cancer Immunol Res. 2014 Apr;2(4):332-40. doi: 10.1158/2326-6066.CIR-13-0136. Epub 2014 Jan 27.

42.

Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.

Wang C, Cicek MS, Charbonneau B, Kalli KR, Armasu SM, Larson MC, Konecny GE, Winterhoff B, Fan JB, Bibikova M, Chien J, Shridhar V, Block MS, Hartmann LC, Visscher DW, Cunningham JM, Knutson KL, Fridley BL, Goode EL.

Cancer Res. 2014 Jun 1;74(11):3084-91. doi: 10.1158/0008-5472.CAN-13-3198. Epub 2014 Apr 11.

43.

Sclerosing adenosis and risk of breast cancer.

Visscher DW, Nassar A, Degnim AC, Frost MH, Vierkant RA, Frank RD, Tarabishy Y, Radisky DC, Hartmann LC.

Breast Cancer Res Treat. 2014 Feb;144(1):205-12. doi: 10.1007/s10549-014-2862-5. Epub 2014 Feb 8.

44.

Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study.

Hartmann LC, Radisky DC, Frost MH, Santen RJ, Vierkant RA, Benetti LL, Tarabishy Y, Ghosh K, Visscher DW, Degnim AC.

Cancer Prev Res (Phila). 2014 Feb;7(2):211-7. doi: 10.1158/1940-6207.CAPR-13-0222. Epub 2014 Jan 30.

45.

Tumorgrafts as in vivo surrogates for women with ovarian cancer.

Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P.

Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7.

46.

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.

Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL.

PLoS One. 2013 Nov 14;8(11):e80063. doi: 10.1371/journal.pone.0080063. eCollection 2013.

47.

APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.

Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, Shridhar V, Bell DA, April C, Bentley D, Bibikova M, Cheetham RK, Fan JB, Grocock R, Humphray S, Kingsbury Z, Peden J, Chien J, Swisher EM, Hartmann LC, Kalli KR, Goode EL, Sicotte H, Kaufmann SH, Harris RS.

Cancer Res. 2013 Dec 15;73(24):7222-31. doi: 10.1158/0008-5472.CAN-13-1753. Epub 2013 Oct 23.

48.

Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.

Cicek MS, Koestler DC, Fridley BL, Kalli KR, Armasu SM, Larson MC, Wang C, Winham SJ, Vierkant RA, Rider DN, Block MS, Klotzle B, Konecny G, Winterhoff BJ, Hamidi H, Shridhar V, Fan JB, Visscher DW, Olson JE, Hartmann LC, Bibikova M, Chien J, Cunningham JM, Goode EL.

Hum Mol Genet. 2013 Aug 1;22(15):3038-47. doi: 10.1093/hmg/ddt160. Epub 2013 Apr 9.

49.

Nutritional status, CT body composition measures and survival in ovarian cancer.

Torres ML, Hartmann LC, Cliby WA, Kalli KR, Young PM, Weaver AL, Langstraat CL, Jatoi A, Kumar S, Mariani A.

Gynecol Oncol. 2013 Jun;129(3):548-53. doi: 10.1016/j.ygyno.2013.03.003. Epub 2013 Mar 21.

PMID:
23523419
50.

Inherited variants in regulatory T cell genes and outcome of ovarian cancer.

Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL.

PLoS One. 2013;8(1):e53903. doi: 10.1371/journal.pone.0053903. Epub 2013 Jan 30.

Supplemental Content

Loading ...
Support Center